Adma Biologics (ADMA) Net Cash Flow (2011 - 2025)
Adma Biologics' (ADMA) quarterly Net Cash Flow came in at $26.2 million in Q4 2025, up 59.64% YoY from $16.4 million in Q4 2024, and up 190.81% on a QoQ basis from -$28.9 million in Q3 2025.
Adma Biologics (ADMA) Net Cash Flow (2011 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Net Cash Flow data on file, last reported at $26.2 million in Q4 2025.
- Quarterly Net Cash Flow rose 59.64% year-over-year to $26.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.5 million (down 129.96% YoY) and the FY2025 annual result came in at -$15.5 million, down 129.96% from the prior year.
- Net Cash Flow climbed to $26.2 million in Q4 2025, from -$28.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $51.6 million in Q4 2022 to a low of -$31.5 million in Q1 2025.
- A 5-year average of $1.6 million and a median of -$3.8 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow jumped 741.44% — and 2025, when it sank 1780.29%.
- Tracing ADMA's Net Cash Flow over 5 years: stood at $16.7 million in 2021, then jumped by 209.48% to $51.6 million in 2022, then tumbled by 144.18% to -$22.8 million in 2023, then soared by 172.09% to $16.4 million in 2024, then soared by 59.64% to $26.2 million in 2025.
- The last three Net Cash Flow figures came in at $26.2 million (Q4 2025), -$28.9 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.25 Mn |
| Dec 31, 2025 | 26.25 Mn |
| Sep 30, 2025 | -28.90 Mn |
| Sep 30, 2025 | -28.90 Mn |
| Jun 30, 2025 | 18.66 Mn |
| Jun 30, 2025 | 18.66 Mn |
| Mar 31, 2025 | -31.52 Mn |
| Mar 31, 2025 | -31.52 Mn |
| Dec 31, 2024 | 16.44 Mn |
| Dec 31, 2024 | 16.44 Mn |
| Sep 30, 2024 | -1.54 Mn |
| Sep 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | 42.92 Mn |
| Jun 30, 2024 | 42.92 Mn |
| Mar 31, 2024 | -6.03 Mn |
| Mar 31, 2024 | -6.03 Mn |
| Dec 31, 2023 | -22.81 Mn |
| Dec 31, 2023 | -22.81 Mn |
| Sep 30, 2023 | 11.64 Mn |
| Sep 30, 2023 | 11.64 Mn |